RE: RE: IS ENDO JUST WAITING TO BUY BIONICHE CHEAPLet's just imagine this scenario for a moment. You will need to think outside the box.
If I'm not mistaken, and please correct me if I'm wrong, Endo does not hold the patents rights for MCC. Bioniche does. Endo does own the distribution rights for Urocidin, worldwide.
Having said that, Endo also knows just how good Urocidin is, which is based on the MCC platform. If this stuff is really as good as they may now know, Endo's biggest fear is not the BNC stock price rising, it's their competition. IMO, Endo is not quite financially ready to make a serious offer to buy BNC's Human Health Division (HHD). But their competitors might be.
Imagine the great news getting out now, shall we. Would Endo be able to win a bidding war to take over BNC's HHD? Let's see now, ..what was that number? ... Ahh yes. Let start at $20 per share. Can Endo afford this price? Maybe not today but they could be in a few months. In the mean time Endo can't have their competitors holding this torch under their nose.
IMO Endo must manage their own affairs first. What we saw in this week's NR was the bare minimum that had to happen. After all BNC was entitled to their milestone regardless of Endo's concerns. And the BNC shareholders are entitled to know that the payment took place.
JMHO
TC9